TE-031 is a new macrolide antibiotic derived from erythromycin. It is highly stable to acid and shows excellent antibacterial activities against Gram-positive and some Gram-negative bacteria. Clinical efficacy of TE-031 in otorhinolaryngological infections was evaluated in 52 cases. TE-031 was administered orally 200mg b. i. d. The efficacy rates were 90.5% for otitis media, 95.7% for tonsillitis and 100% for sinusitis as judged by treating doctors, and 90.5% for otitis media, 91.3% for tonsillitis and 100% for sinusitis as judged by the committee. Side effects were observed in 3 cases (5.8%) but the symtoms disappeared after the use of TE-031 was discontinued. Clinical usefulness was judged by treating doctors to be 90.5% for otitis media, 91.3% for tonsillitis and 80.0% for sinusitis, and by the committee to be 90.5% for otitis media, 91.3% for tonsillitis and 80.0% for sinusitis. TE-031 appears to be a useful drug for the treatment of otorhinolaryngological infections.
